Basics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
|
|
- Magdalen Pope
- 5 years ago
- Views:
Transcription
1 Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018
2 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated that the number of patients with T1DM using CSII was ~375,000 By 2050, up to one-third of US residents may have T2DM; many of these individuals will be insulinrequiring Therefore, more clinicians must develop a comprehensive understanding of these devices HSBC Global Research. Healthcare US Equipment & Supplies U.S. FDA. General Hospital and Personal Use Medical Devices Panel U.S. CDC. CDC Media Relations - Press Release: October 22, T1DM: type 1 diabetes mellitus T2DM: type 2 diabetes mellitus FDA: U.S. Food and Drug Administration CSII: continuous subcutaneous insulin infusion
3 History of insulin pumps Outline Benefits of improved glycemic control Advantages of insulin pump therapy Inpatient Insulin pump management Carbohydrate Counting Hypoglycemia and hyperglycemia prevention Conclusions
4 Best and Banting
5 Evolution of Diabetes Management Technologies Insulin Pump Therapy Glucose Sensors BG Meters Urine Test Strips Urine Tasting 1776 Discovery of Insulin 1900s Artificial Pancreas
6 First Insulin Pump (1963 by Dr. Arnold Kadish)
7 Early Insulin Pumps
8 Insulin Pumps
9 Insulin Pumps on the Market Accu-Chek Combo System Asante Snap Insulin Pump System MiniMed Paradigm Real-Time Revel System (523/723) MiniMed 530G with Enlite (551/751) OmniPod Insulin Management System OneTouch Ping t:slim Insulin Pump V-Go Disposable Insulin Delivery Device Roche Health Solutions Asante Solutions Medtronic MiniMed Medtronic MiniMed Insulet Corporation Animas Tandem Diabetes Care Valeritas, Inc.
10 U.S. Pump Usage Total Patients Using Insulin Pumps 200, , , , ,000 81,000 60,000 50,000 6,600 8,700 11,400 15,000 20,000 43,000 35,000 26,500 0 '90 '91 '92 '93 '94 '95 '96 '97 '98 '
11 How Diabetes Specialists Treat Their Own Type 1 Diabetes AADE Membership n=229 60% ADA Membership n=293 52% Color Key: Pump Therapy General Type 1 Population* 6% Injections Industry estimates at time of survey (9/98); Graff: Diabetes Educator 2000; 46:
12 Outline History of insulin pumps Benefits of improved glycemic control Advantages of insulin pump therapy Inpatient Insulin pump management Carbohydrate Counting Hypoglycemia and hyperglycemia prevention Conclusions
13 RISK Potential Chronic Complications of Elevated HbA1c Microalbuminuria Mild Retinopathy Mild Neuropathy Foot Ulcers Angina Heart Attack Coronary Bypass Surgery Stroke Blindness Albuminuria Amputation Macular Edema Dialysis Proliferative Kidney Retinopathy Transplant Peridontal Disease Impotence Gastroparesis Depression Good CONTROL Poor
14 DCCT Microvascular Risk Reduction With Intensive Treatment Complication Reduction in Relative Risk Retinopathy 63% Nephropathy 54% Neuropathy 60% Data from the Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:
15 Treatment Strategies for Diabetes: Are Patients Achieving Good Control? Hypertension Hyperlipidemia Glycemic control BP <140/90 mm Hg LDL-C <130 mg/dl A1C <7.0 41% 41% 42% 59% 59% 58% Controlled Uncontrolled Harris MI et al. Diabetes Care. 2000;23:754
16 Outline History of insulin pumps Benefits of improved glycemic control Advantages of insulin pump therapy Inpatient Insulin pump management Carbohydrate Counting Hypoglycemia and hyperglycemia prevention Conclusions
17 The Goal of Insulin Therapy: Attempt to Mimic Normal Pancreatic Function PLASMA GLUCOSE mg/dl PLASMA FREE INSULIN u/ml Schade, Skyler, Santiago, Rizza, Intensive Insulin Therapy, 1993, p B L S HS HOURS
18 Insulin Effect Twice-daily Split-mixed Regimens Regular NPH B L S HS B 6-23
19 Insulin Effect Basal Bolus Regimen with Glargine and Lispro lispro Glargine B L S HS B 6-56
20 Insulin Effect Continuous Subcutaneous Insulin Infusion Bolus Basal B L S HS B
21 Pharmacokinetics of CSII vs MDI Uses immediate acting insulin More predictable absorption Uses one injection site Reduces variations in absorption Eliminates most of the subcutaneous insulin depot Closest match with physiologic needs * Lauritzen: Diabetologia 1983; 24:326-9
22 Type 1 Diabetes A 2010 Cochrane review compared the use of CSII vs. MDI insulin regimens (23 randomized studies involving 976 patients with T1DM) A significant difference was documented in HbA 1c response, favoring CSII CSII users demonstrated greater improvements in quality of life measures Severe hypoglycemia appeared to be reduced in CSII users Misso ML, et al. Cochrane Database Syst Rev. 2010;(1):CD doi(1):cd CSII: continuous subcutaneous insulin infusion MDI: multiple daily injection T1DM: type 1 diabetes mellitus
23 Type 1 Diabetes The STAR-3 study showed significantly greater HbA 1c reductions in patients with T1DM randomly assigned to sensor-augmented insulin pump therapy vs. MDI A higher proportion of patients randomly assigned to pump therapy achieved an HbA 1c <7% without any increase in severe hypoglycemia rates or weight gain vs. the MDI group Based on currently available data, CSII is justified for basal-bolus insulin therapy in patients with T1DM Bergenstal RM, et al. N Engl J Med. 2010;363(4): STAR-3: Sensor-Augmented Pump Therapy for A1C Reduction T1DM: type 1 diabetes mellitus MDI: multiple daily injection CSII: continuous subcutaneous insulin infusion
24 Trial Evidence: CSII versus MDI use in Population: Comparison of glycemic control in 58 patients while on MDI x 3yrs and subsequent CSII x 3yrs Methods: Mean HbA1c% routine clinical practice Retrospective, observational cohort study of patients with Type 1 diabetes P= P= P= MDI CSII Bell and Ovalle, Endocr Pract 2000;6: Entire Cohort MDI HbA1c >8.0% MDI HbA1c >9.0%
25 Improved Control and Less Variability Glucose (mg/dl) 400 Pump Therapy With Pump Therapy Finger Stick Sensor Multiple Daily Injections Glucose (mg/dl) 400 Finger Stick Sensor :00 a.m.6:00 a.m. 12:00 p.m.6:00 p.m. 12:00 a.m. Time (Day) :00 a.m.6:00 a.m. 12:00 p.m.6:00 p.m. 12:00 a.m. Time (Day)
26 Improved Control: Decreased Hypoglycemia Episodes per 100 pt yrs N=55 0 Pre CSII 1 yr 2 yr 3 yr 4 yr With CSII Bode et al: Diabetes Care 1996; 19:324-7
27 (episodes / 100 pt years) Diabetic Ketoacidosis Pre-CSII 7 Post-CSII Bode, BW, Diabetes Care 19:324-7, 1996.
28 Pediatric Patients Pediatric diabetes specialists agree that CSII is indicated for pediatric patients with: Elevated HbA 1c levels on injection therapy Frequent, severe hypoglycemia Widely fluctuating glucose levels A treatment regimen that compromises lifestyle Microvascular complications and/or microvascular risk factors Ideal pediatric candidates have motivated families, with a working understanding of diabetes management, and committed to monitoring blood glucose 4 times/day Patient age and duration of diabetes should not be factors in determining the transition from injections to CSII Phillip M, et al. Diabetes Care. 2007;30(6): CSII: continuous subcutaneous insulin infusion
29 Challenges of Pump Therapy Learning curve Risk of DKA Possible weight gain Frequent monitoring required Potential site infections Inconvenience in wearing pump Education and follow-up required Cost
30 Advantages of Pump Therapy- Summary Improved blood glucose control Improved AIC s Decreased hypoglycemia and hyperglycemia Delay in incidence and progression of complications Precise dosage delivery Improved control for pre-conception and pregnancy Management of dawn phenomenon Increased flexibility in lifestyle Improved control during exercise Improved gastroparesis management
31 Outline History of insulin pumps Benefits of improved glycemic control Advantages of insulin pump therapy Inpatient Insulin pump management Carbohydrate Counting Hypoglycemia and hyperglycemia prevention Conclusions
32 Insulin Pumps in Inpatient Settings When Insulin pump users are evaluated for a non-acute hyper- or hypoglycemic crisis, they typically have more insulin pump knowledge and expertise than the medical professionals handling their hospital stay At emergency room or hospital admission, the specialist(s) responsible for the patient s ambulatory pump management should be contacted promptly to make decisions about infusion adjustments Patients should be instructed to not discontinue the pump infusion, unless directed by their diabetes specialist CSII: continuous subcutaneous insulin infusion
33 Key Components of Insulin Pump Settings Basal Rate: Rate at which rapid acting insulin is delivered as a continuous subcutaneous flow Expressed as units/ hour. The patient may have multiple basal rates programmed during the 24 hour period. Carb Ratio: The predicted amount of insulin needed per gram of carbohydrate for a specific meal or snack. (e.g., 1 unit insulin needed for10 grams of carbohydrate) Correction factor/ Sensitivity factor: The amount that blood glucose (mg/dl or mmol/l) will be reduced by 1 unit of insulin. (e.g a correction factor of 50 means that 1 unit of insulin will reduce BG by 50 mg/dl)
34 Determine Competency To Continue Insulin Pump Inpatient Can open the management menu of the device Are able to adjust the basal rate Are able to adjust the bolus dose Can demonstrate technical competency Can undertake appropriate problem solving actions if blood sugars are high or low Have adequate supplies of infusion sets, spare batteries and the insulin vials Have been performing regular blood glucose monitoring tests
35 Contraindications for using Insulin Pump Inpatient Patients with an impaired level of consciousness Patients with critical illness requiring intensive care Patients with major psychiatric disturbance Diabetic ketoacidosis Patients refusing or unwilling to participate in self care Lack of infusion sets, spare batteries and other equipment required to maintain patient on CSII therapy
36 Documentation It must be clearly written in the medical record that the patient is on an insulin pump The brand name and model of the pump must be written in the medical record The type of insulin used in the insulin pump must be identified and recorded in the blood glucose monitoring form The current basal and bolus insulin doses must be documented in the medical record Ideally the pump data would be downloaded and the print out stored in the medical chart
37 Medtronic Pump Download
38 Practice Question A 63 year-old man is evaluated during a follow-up visit for management of type 1 diabetes mellitus. He was diagnosed at 18 years of age and has multiple chronic complications from his diabetes, including end-stage kidney disease requiring hemodialysis, gastroparesis, frequent hypoglycemia with hypoglycemic unawareness, painful peripheral neuropathy, and proliferative retinopathy. The patient uses an insulin pump and a continuous glucose monitoring system to manage his diabetes. He is adherent with his regimen and performs multiple fingerstick blood glucose measurements with values ranging from 65 to 250 mg/dl ( mmol/l). His most recent hemoglobin A1c level is 7.5%
39 Which of the following is the most appropriate next step in the management of this patient? (a) Alter insulin pump settings to attain a hemoglobin A1c goal of less than 7.0% (b) Alter insulin pump settings to decrease the insulin doses (c) Discontinue the insulin pump, start subcutaneous insulin injections (d) Start gabapentin for the treatment of painful peripheral neuropathy
40 (b) Alter insulin pump settings to decrease the insulin doses KEYPOINT A less stringent hemoglobin A1c goal is appropriate for persons with diabetes mellitus with a decreased life expectancy, history of severe hypoglycemia, multiple comorbidities, or advanced microvascular or macrovascular disease
41 Consultations Endocrinologist or Physician with interest in diabetes Diabetes Educator or diabetes resource person trained in insulin pump management Dietitian
42 Monitor BG Monitoring Fasting in the morning Pre-meals Bedtime Assess basal insulin dose by fasting and premeal BG s Adjust nighttime basal based on pre-breakfast BG Adjust basal rate by 10% to avoid over-correction
43 Healthcare Across Borders CGM Benefits Increased sense of security Immediate feedback look and learn Improves control when used Worth out of pocket cost for many One unit available for about a Starbucks a day Reimbursement gradually catching on
44 Do You Need to Remove Pump? Any radiological investigation (pump must be removed) CT Scan (pump must be removed) MRI scan (pump must be removed, including metal cannula) Physiotherapy (depending on the therapy) Hydrotherapy (even if the pump is labeled as water-proof)
45 Specific Scenarios 63 year old type 2 diabetic patient scheduled for cardiac angiogram. NPO after midnight 21 year old type 1 diabetic woman getting parathyroidectomy the next day. NPO after midnight 40 year old woman with type 1 diabetes admitted for Pneumonia 36 year old man with type 1 diabetes in DKA 55 year old man with type 1 diabetes getting colonoscopy
46 Outline History of insulin pumps Benefits of improved glycemic control Advantages of insulin pump therapy Inpatient Insulin pump management Carbohydrate Counting Hypoglycemia and hyperglycemia prevention Conclusions
47 Pre-meal boluses: Bolus Dose Insulin Taken before meals Covers mealtime carbohydrate intake Prevents postprandial hyperglycemia Correction or supplementation boluses: Used to Correct and treat hyperglycemia May be given alone between meals for hyperglycemia May be given to supplement already scheduled insulin to cover pre-meal hyperglycemia
48 Why Count Carbs? It works Increases flexibility in food choices and the amounts of foods consumed Easy to understand Well-accepted
49 Macronutrient Conversion to Blood Glucose
50 Carbohydrate Counting Benefits Allows for variation in appetite and preferences Increases variety of food choices Can be used to match insulin bolus doses to food intake
51 Carb Counting and Insulin Bolusing Insulin-to-Carb Ratio EXAMPLE: 1 unit insulin: 15 grams CHO Sample Meal 1 c. orange juice 30 g 2 slices toast 30 g ½ c. oatmeal 15 g 1 soft-cooked egg 1 tsp margarine Coffee & 1 T cream Total CHO: 75 g Insulin bolus: 5 units Sample Meal 2 slices wheat bread 30 g 2 oz. turkey breast Lettuce leaf, tomato slice 1 tsp mayonnaise ring pretzels 15 g 2 small choc cookies 15 g Diet soda, 16 oz Total CHO: 60 g Insulin bolus: 4 units
52 Outline History of insulin pumps Benefits of improved glycemic control Advantages of insulin pump therapy Inpatient Insulin pump management Carbohydrate Counting Hypoglycemia and hyperglycemia prevention Conclusions
53 Preventing Hypoglycemia Check BG 4-6 times per day Carry glucose tablets Have Glucagon Kit available
54 Hypoglycemia Treatment Guidelines The Rule of 15 If BG is 70 mg/dl or below Treat with 15 grams of carbohydrates (glucose tabs) Check BG in 15 minutes, and if not above 70 mg/dl, repeat treatment Glucagon Current emergency kit readily available and knowledgeable person trained to administer
55 Preventing Hyperglycemia and DKA Monitor BG 4-6 times per day Use Correction Boluses when appropriate Change infusion set every 2-3 days
56 Conclusions Insulin Pump Therapy is becoming widely recognized as the best way to treat insulin requiring diabetes Insulin pump is now considered standard of care in appropriate patients Pump Therapy has advantages over multi-dose therapy Insulin pumps can be continued in most patients who are admitted to the hospital
Advances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationHigh rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study.
High rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study. Dr. Eugene Merzon MD; Ilia Merhasin, MBA; Dr. Avivit Golan-Cohen MD ; Dr. Shmuel
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationWhat is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?
What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More information06/13/17. A. Completed a comprehensive diabetes education program within the past two years; and
Reference #: MC/L011 Page 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA
More information123 Are You Providing Evidence-Based Diabetes Care? - Martin
Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationTechnology for Diabetes: 101 Basic Rules of the Road. Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE
Technology for Diabetes: 101 Basic Rules of the Road Karen Hamon RN, BSN, CDE Stephen Stone MD, FAAP Neil H. White, MD, CDE Quick Pump Facts! o Constant insulin supply o Pager-sized mini-computer worn
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationPerformance-powered. The OneTouch. Ping insulin pump and meter-remote.
Performance-powered. The OneTouch Ping insulin pump and meter-remote. I We don t just deliver insulin. We deliver outstanding clinical performance. P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 OneTouch Ping.
More informationFigure 2.1: Glucose meter
CHAPTER TWO: MONITORING TECHNOLOGIES 2.1 Introduction Glucose monitoring is a method of self-testing glucose (blood sugar) levels for the management of diabetes. Traditionally, it involves pricking the
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationDIAGNOSIS OF DIABETES NOW WHAT?
DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO
More informationCalgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations
Calgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations This is a long and important document. It lists the steps for starting insulin pump therapy at the Calgary Diabetes Centre. It
More informationInsulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education
Insulin Pumps and Continuous Glucose Sensors- Embracing Technology Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education Diabetes Management Tools in 1974 Insulin pump history
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationPumping Insulin is it for your patients?
Pumping Insulin is it for your patients? YOU CAN make managing diabetes easier. Fred Porcase D.O. Disclosures to Participants Conflicts Of Interest and Financial Relationships Disclosures: No professional
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationType 1 Diabetes Update Robin Goland, MD
Naomi Berrie Diabetes Center Type 1 Diabetes Update 2008 Robin Goland, MD Type 1 diabetes is: A manageable condition A chronic condition Often challenging Entirely compatible with a happy and healthy childhood
More informationUSE OF INSULIN PUMP FOR THE 1 ST TIME IN A GOVERNMENT HOSPITAL JJ HOSPITAL, MUMBAI
USE OF INSULIN PUMP FOR THE 1 ST TIME IN A GOVERNMENT HOSPITAL JJ HOSPITAL, MUMBAI Dr. Hemant Gupta [Associate Prof. & Unit Head, Dept of Medicine, J.J.Hospital, Mumbai] Dr. Ayaz Ahmed [lecturer] Dr. Parag
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationPhysical Activity/Exercise Prescription with Diabetes
Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationUNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE
UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE The insulin pump Replaces injections Delivers insulin through a soft cannula
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationDesigned with your patients lives in mind
The Accu-Chek Insight diabetes therapy system Designed with your patients lives in mind With pre-filled insulin cartridge Designed for easy patient training The Accu-Chek Insight diabetes therapy system
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Final scope Appraisal objective To review
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationIn general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.
1 2 3 In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 4 Answer: b and c Many alcohol containing drinks
More informationApproved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.
Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationChapter 37: Exercise Prescription in Patients with Diabetes
Chapter 37: Exercise Prescription in Patients with Diabetes American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationStandard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8
Standard Operating Procedure 11 Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8 Date Version Issue Review Contact Approved Date Date Person October 2013 9 October 2013 March
More informationWHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?
Christian In better control with his pump since 2012 WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Many people with Type 1 diabetes worry about potential long-term
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 05/24/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationCalgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations
Calgary Diabetes Centre Insulin Pump Therapy: Preparation and Expectations This is a long and important document. It lists the steps for starting insulin pump therapy at the Calgary Diabetes Centre. It
More informationInsulin Pumps - External
Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of
More informationFine-tuning of The Dose of Insulin Pump
Fine-tuning of The Dose of Insulin Pump The manual does not guarantee specific individual or specific applicability of the environment, there is no express or implied warranties. Contents of this manual
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 07/10/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationDiabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018
Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018 Pumps & Sensors & Meters, Oh My! A Tale of Two Meters Technology for glucometers
More informationREPORT INTERPRETATION
REPORT INTERPRETATION: Interpreting ipro Professional Continuous Glucose Monitoring (CGM) Reports and Making Therapy Adjustments TARGET AUDIENCE The audience for this section is physicians, mid-level practitioners,
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationImplementing Hospital Policies & Protocols
Implementing Hospital Policies & Protocols Jane Jeffrie Seley DNP MPH GNP BC-ADM CDE CDTC FAADE FAAN Division of Endocrinology, Diabetes & Metabolism NewYork-Presbyterian Hospital Weill Cornell Medicine
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationUNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE
UNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE 1 LEARNING OBJECTIVES By the end of this session participants should be able to understand: The benefits of bolus advisors The
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association.
Insulin Pump Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association. Title: Insulin Pump Professional Original Effective Date: January 1, 1999 Revision Date(s): June
More information10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:
DEXCOM G5 MOBILE CGM COMPATIBLE B 100% 235 u INSULIN ON BOARD: OPTIONS 10:20 AM March 5, 2017 400 350 300 250 200 150 100 50 1.1 u 1:09 hrs BOLUS 124 mg/dl 3 HRS The pump that gets updated, not outdated.
More informationContinuous Glucose Monitoring
Continuous Glucose Monitoring What is Continuous Glucose Monitoring? Blood glucose meters measure glucose in your blood and glucose sensors measure glucose levels in the fluid around the cells They are
More informationPredicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY
Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for
More informationMuch of what is written on insulin pump use is biased in favor of insulin pump manufacturers.
CHAPTER 2: ADVANTAGES AND DISADVANTAGES OF INSULIN PUMPS H. Peter Chase, MD Much of what is written on insulin pump use is biased in favor of insulin pump manufacturers. There are many people who are able
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationInterpretation of Continuous Glucose Monitoring (CGM) Data
Interpretation of Continuous Glucose Monitoring (CGM) Data Sherri Horvat, BSN, RN, CDE Blood Glucose Manager, Animas Corporation A Johnson & Johnson Diabetes Care Company Overview of CGM Continuous glucose
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationCurrent Status: Retired PolicyStat ID: Effective: 03/2017 Approved: 03/2017 Last Revised: 03/2017 Expiration: 03/2020
Current Status: Retired PolicyStat ID: 3428552 Effective: 03/2017 Approved: 03/2017 Last Revised: 03/2017 Expiration: 03/2020 Owner: Department: References: Dustin Falk: Clinical Coordinator- Pharmacy
More informationInsulin Pump Therapy. WakeMed Children s Endocrinology & Diabetes WakeMed Health & Hospitals Version 1.3, rev 5/21/13 MP
Insulin Pump Therapy WakeMed Children s Endocrinology & Diabetes Overview What is an insulin pump? What are the advantages and disadvantages of an insulin pump? Lifestyle Changes Food Management Exercise
More informationWHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE
WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE MAY 5, 2018 OBJECTIVES Strong understanding of diabetes and its management
More informationWith new technology available to
Insulin Pump Therapy: Who, Why, and How Alyssa Kanagaki Greenleaf, BA, MHS, PA-C With new technology available to aid patients, diabetes management in the 21st century is moving beyond metformin. Among
More informationSARASOTA MEMORIAL HOSPITAL
SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE MANAGEMENT OF PATIENT S OWN INSULIN PUMP/CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP (dia13) DATE: REVIEWED: PAGES: 08/84 11/18 1 of 7 PS1094 ISSUED
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationDiabetes Medical Management Plan
Diabetes Medical Management Plan 1 School District: School: School Year: Grade: Student Name: DOB: Provider Name: Phone #: Fax #: Blood Glucose Monitoring at School Blood Glucose Target Range: - mg/dl
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More information[Insert School Logo] School Grade Teacher Physician Phone Fax Diabetes Educator Phone 504 Plan on file Yes No
[Insert School Logo] 1 INDIVIDUALIZED HEALTH PLAN (IHP for SCHOOLS): DIABETES WITH PUMP Picture of Student Student DOB Home Phone Mother Work Phone Cell Phone Father Work Phone Cell Phone Guardian School
More informationType 1 Diabetes & Continuous Glucose Monitoring. Dr Sheila Cook Director of Diabetes & Endocrinology Toowoomba Hospital
Type 1 Diabetes & Continuous Glucose Monitoring Dr Sheila Cook Director of Diabetes & Endocrinology Toowoomba Hospital Let s consider the traditional diabetes clinic The Diabetes Clinic Whenever I check
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More information